NDAORALTABLET
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Clinical Trials (5)
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
Started Oct 2025
0Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Started Oct 2025
126 enrolled
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
Started Apr 2025
0Prostate CancerCastrate Resistant Prostate CancerHomologous Recombination Deficiency
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Started Feb 2025
252 enrolled
mCRPC (Metastatic Castration-resistant Prostate Cancer)Genital Neoplasms, MaleUrogenital Neoplasms+7 more
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Started Jan 2025
72 enrolled
Recurrent Prostate CarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
Loss of Exclusivity
LOE Date
May 20, 2034
99 months away
Patent Expiry
May 20, 2034